AirNexis Therapeutics

Summary

AirNexis Therapeutics, developer of a COPD drug, raised $200 million in Series A funding led by Frazier Life Sciences, with participation from OrbiMed, SR One, Goldman Sachs Alternatives, Longitude Capital, and Enavate Sciences.